Valcon Medical A/S - CVR: 40086714

2023, EUR

30.06.2024

Bruttoresultat

-15.119'

Primær drift

Na.

Årets resultat

-30.262'

Aktiver

50.294'

Kortfristede aktiver

13.746'

Egenkapital

38.684'

Afkastningsgrad

0 %

Soliditetsgrad

77 %

Likviditetsgrad

241 %

Resultat

30.06.2024

Årsrapport	2023 30.06.2024	2022 03.07.2023	2021 24.06.2022	2020 29.06.2021	2018 31.08.2020
Nettoomsætning
Bruttoresultat	-15.119.165	-15.349.994	-6.235.445	-1.132.718	-3.020.603
Resultat af primær drift	0	0	-12.886.700	-3.828.076	-5.530.797
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	71.473	18.292	1.991	98.679	0
Finansieringsomkostninger	-1.313.604	-585.872	-1.437.435	-785.847	-38.800
Andre finansielle omkostninger	0	0	0	0	0
Resultat før skat	0	0	-14.322.144	-4.515.244	-5.569.597
Resultat	-30.261.603	-17.079.193	-10.627.248	-3.518.179	-4.344.377
Forslag til udbytte	0	0	0	0	0

Aktiver

30.06.2024

Årsrapport	2023 30.06.2024	2022 03.07.2023	2021 24.06.2022	2020 29.06.2021	2018 31.08.2020
Kortfristede varebeholdninger	9.552.478	6.143.613	816.317	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	2.882.673	9.902.812	6.507.985	2.638.462	2.669.208
Likvider	1.310.352	6.627.149	11.994.152	4.405.547	6.895.182
Kortfristede aktiver	13.745.503	22.673.574	19.318.454	7.044.009	9.564.390
Immaterielle aktiver og goodwill	9.572.927	12.044.406	7.906.488	0	0
Finansielle anlægsaktiver	4.087.225	5.558.020	263.100	263.100	263.100
Materielle aktiver	22.888.308	26.978.637	29.664.579	25.232.682	5.331.601
Langfristede aktiver	36.548.460	44.581.063	37.834.167	25.495.782	5.594.701
Aktiver	50.293.963	67.254.637	57.152.621	32.539.791	15.159.091

Aktiver

30.06.2024

Passiver

30.06.2024

Årsrapport	2023 30.06.2024	2022 03.07.2023	2021 24.06.2022	2020 29.06.2021	2018 31.08.2020
Forslag til udbytte	0	0	0	0	0
Egenkapital	38.684.019	56.675.233	49.435.413	639.542	9.655.623
Hensatte forpligtelser	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld		0	0	25.083.806	2.700.000
Leverandører af varer og tjenesteydelser	2.656.898	1.366.257	1.838.590	5.214.141	2.383.897
Kortfristede forpligtelser	5.704.792	4.186.313	5.915.929	6.816.443	2.803.468
Gældsforpligtelser	11.609.944	10.579.404	7.717.208	31.900.249	5.503.468
Forpligtelser	11.609.944	10.579.404	7.717.208	31.900.249	5.503.468
Passiver	50.293.963	67.254.637	57.152.621	32.539.791	15.159.091

Passiver

30.06.2024

Nøgletal

30.06.2024

Årsrapport	2023 30.06.2024	2022 03.07.2023	2021 24.06.2022	2020 29.06.2021	2018 31.08.2020
Afkastningsgrad	Na.	Na.	-22,5 %	-11,8 %	-36,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-78,2 %	-30,1 %	-21,5 %	-550,1 %	-45,0 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	-896,5 %	-487,1 %	-14.254,6 %
Soliditestgrad	76,9 %	84,3 %	86,5 %	2,0 %	63,7 %
Likviditetsgrad	240,9 %	541,6 %	326,5 %	103,3 %	341,2 %

Resultat

30.06.2024

Gæld

30.06.2024

Årsrapport

30.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 30.06.2024)

Information om virksomhedens regnskabsklasse:The annual report of Valcon Medical A/S for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year. The annual report for 2023 is presented in DKK

Oplysning om pantsætninger og sikkerhedsstillelser:All assets has been pledged with a company pledged of DKK 5,3 mill.

Beretning

30.06.2024

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The supervisory board and executive board have today discussed and approved the annual report of Valcon Medical A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Valcon Medical is a European manufacturing company specializing in medical cannabis extracts. The company sells white-label products, extracts in bulk, and contract manufacturing services. Our promise is to deliver the highest-quality products while ensuring a consistent and scalable supply. Valcon Medical is GMP-certified by the Danish Medicines Agency under national law governing medical cannabis. Products are manufactured under EU-GMP standards and tested in accordance with DAB Eingestellter Cannabisextract and the European Pharmacopeia (Ph. Eur. ). First Operational Year Highlights 2023 marked Valcon Medical's first full operational year following our initial shipment to Germany in late 2022. As a commercial startup year, we saw promising developments with several recurring orders and positive feedback on quality from our white-label partners across Europe. This positive reception underscores our commitment to delivering high-quality products and services. Expansion and New Supply Agreements Throughout 2023, Valcon Medical entered supply agreements with several new customers across various jurisdictions. The onboarding of these new customers began, and we anticipate that the full results of these efforts will become evident in 2024. These agreements represent significant steps toward expanding our market reach and establishing a stronger foothold in the European medical cannabis market. Challenges and Achievements in Denmark Despite our successes, we faced delays in product approvals in Denmark. These activities, managed by our subsidiary Scanleaf, did not meet our initial expectations. However, we achieved a significant milestone with the product approval finally received in December 2023, leading to the commencement of product sales in Denmark in 2024. This achievement is crucial for our strategic growth in the Danish market. Cost Reduction and Organizational Restructuring In 2023, we undertook essential actions to reduce costs and streamline operations. This included restructuring the organization and reducing the workforce. Midway through the year, we assessed that our inventory of intermediate goods was sufficient to support the manufacturing of final goods for sale in 2024 and most of 2025. Consequently, in 2024, we will focus solely on producing finished goods ready for sale. This strategy, which involves maintaining a stock of long shelf-life intermediate goods, allows us to meet customer orders with a short lead time for the next two years. Stabilization and Future Scalability The right-sizing of our organization and the reduction of fixed and variable costs have brought Valcon Medical to a stable operational platform. This foundation can be scaled up as needed, positioning us well for future growth. The efforts made in 2023 to secure new customers and obtain product approvals in Denmark have already begun to show results in 2024, proving the effectiveness of our strategic plan. We anticipate a significant increase in revenue in the coming year. Financial Position and Future Prospects Valcon Medical’s growth plans require additional financing. Management expects to complete the necessary funding by the end of July 2024. Valcon Medical expects to reach profit break even already in its third operational year, 2025.